Clinical Trial Update: Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating carfilzomib to prevent relapse and graft-versus-host disease in allogeneic stem cell transplant for hematologic malignancies…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Hematologic Malignancies
• Relapse

Drugs mentioned

• Carfilzomib (carfilzomib)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Hematologic Malignancies, Relapse | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-01-06